Clinical TrialsCX-801 Phase 1 trial starts patient dosing, exploring its potential in both traditionally immune-oncology sensitive and insensitive tumors.
Innovation In Cancer TreatmentCX-801 is designed to evaluate safety and clinical activity, both as a standalone treatment and in combination with Merck & Co.'s KEYTRUDA, which could significantly enhance cancer therapy options.
Research And DevelopmentThe therapeutic window for CX-904 is much wider than for other probody therapeutics, indicating promising potential for future applications in oncology.